OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Campos on Next Steps With PARP Inhibitors in Ovarian Cancer

October 15th 2018

Susana M. Campos, MD, gynecologic oncologist, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses next steps with PARP inhibitors in ovarian cancer.

Dr. Gandara on Practice-Changing Studies in Lung Cancer

October 13th 2018

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer, a 2017 Giant of Cancer Care in Lung Cancer®, discusses practice-changing studies in lung cancer.

The Importance of Curiosity in Expanding Cancer Immunology

October 13th 2018

Jill O'Donnell-Tormey, PhD, chief executive officer, director of scientific affairs, Cancer Research Institute, discusses the importance of curiosity in expanding the role of immunology in the treatment of cancer.

Dr. Upadhyaya on Outcomes for Children on the SJYC07 Trial

October 12th 2018

Santhosh Upadhyaya, MD, neuro-oncologist, St. Jude Children’s Research Hospital, discusses outcomes for children enrolled on the SJYC07 trial.

Dr. Sharma Discusses Immune Checkpoint Resistance in GU Cancers

October 12th 2018

Padmanee Sharma, MD, PhD, professor of Immunology in the Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses immune checkpoint resistance in genitourinary cancers.

Dr. Cohen Discusses Combination Therapy in MCL

October 12th 2018

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses combination therapy for patients with mantle cell lymphoma.

Cosmo Smith on How Origin Improves Patient Access

October 12th 2018

P. Cosmo Smith, managing partner, Origin Commercial Ventures, discusses how Origin improves patient access in oncology.

ESMO Asia mCRC Guidelines: Insights on Impact and Uptake

October 12th 2018

Optimal Sequence of Therapies for R/M SCCHN

October 12th 2018

Dr. Martin on Autologous Stem Cell Transplant in Multiple Myeloma

October 12th 2018

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, and associate director, Myeloma Program, University of California, San Francisco; co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses autologous stem cell transplant (ASCT) in multiple myeloma.

Dr. Borghaei on Molecular Profiling in Lung Cancer

October 12th 2018

Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses molecular profiling in lung cancer.

Dr. Radich on Compliance to NCCN Guidelines in CML

October 12th 2018

Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses compliance to the NCCN guidelines in the treatment of patients with chronic myeloid leukemia (CML).

Dr. O'Donnell Compares Checkpoint Inhibitors in Bladder Cancer

October 12th 2018

Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, compares checkpoint inhibitors in the treatment of patients with bladder cancer.

Dr. Sweis on Sequencing of Therapies in Prostate Cancer

October 12th 2018

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses the sequencing of therapies in prostate cancer.

Dr. Melisko Reflects on Findings From the MINDACT Trial in Breast Cancer

October 11th 2018

Michelle E. Melisko, MD, associate clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, reflects on the findings from the MINDACT trial in breast cancer.

Dr. Ginsburg Discusses the Use of VIA in Cervical Cancer Screening

October 11th 2018

Ophira Ginsburg, MD, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, discusses the use of visual inspection with acidic acid (VIA) in cervical cancer screening.

Dr. Flaherty Discusses BRAF Inhibitors in Melanoma

October 11th 2018

Keith T. Flaherty, MD, director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, professor of medicine, Harvard Medical School, discusses BRAF inhibitors for the treatment of patients with melanoma.

Dr. Forster on Next Steps With Lurbinectedin in SCLC

October 11th 2018

Martin Forster, MD, a medical oncologist, University College London Hospitals, discusses the next steps with the investigational agent lurbinectedin in combination with doxorubicin as a second-line therapy for patients with small cell lung cancer (SCLC).

Dr. Papadimitrakopoulou on Biomarker-Driven Clinical Trials in NSCLC

October 11th 2018

Vassiliki Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses biomarker-driven clinical trials in non–small cell lung cancer.

Dr. Zarour on Unmet Needs in Melanoma

October 10th 2018

Hassane M. Zarour, MD, professor of medicine, University of Pittsburgh, discusses unmet needs in melanoma.